Alethia Young analyst CANTOR FITZGERALD

Currently out of the existing stock ratings of Alethia Young, 255 are a BUY (79.69%), 59 are a HOLD (18.44%), 6 are a SELL (1.88%).

Alethia Young

Work Performance Price Targets & Ratings Chart

Analyst Alethia Young, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 61% that have a potential upside of 50.54% achieved within 370 days.

Alethia Young’s has documented 614 price targets and ratings displayed on 53 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on RCUS, Arcus Biosciences at 04-Jul-2024.

Wall Street Analyst Alethia Young

Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/3/2020. The price target of $278 was fulfilled within 1 day with a profit of $30.99 (12.55%) receiving and performance score of 125.46.

Average potential price target upside

ACHN Achillion Pharmaceuticals ADVM Adverum Biotechnologies AGIO Agios Pharm ALNY Alnylam Pharmaceuticals AMGN Amgen ARNA Arena Pharmaceuticals ARWR Arrowhead Pharmaceuticals ASND Ascendis Pharma AS BIIB Biogen FATE Fate Therapeutics GILD Gilead Sciences ICPT Intercept Pharmaceuticals INCY yte PBYI Puma Biotechnology PTCT PTC Therapeutics RAPT RAPT Therapeutics REGN Regeneron Pharmaceuticals SPPI Spectrum Pharmaceuticals SRPT Sarepta Therapeutics TGTX TG Therapeutics VRTX Vertex Pharmaceuticals BMRN Biomarin Pharmaceutical AA Alcoa Corp AKBA Akebia Ther ALXN Alexion Pharmaceuticals ARVN Arvinas AUPH Aurinia Pharmaceuticals CELG Celgene CLF Cleveland-Cliffs CRIS Curis FCX Freeport-McMoran Copper & Gold GBT Global Blood Therapeutics MYOK MyoKardia PRVB Provention Bio ELDN Eledon Pharmaceuticals UTHR United Therapeutics CLVS Clovis Oncology NKTX Nkarta  NEXI Neximmune MRNS Marinus Pharmaceuticals STML Stemline Therapeutics STOK Stoke Therapeutics THRX Theseus Pharmaceuticals VSTM Verastem LBPH Longboard Pharmaceuticals ALXO Alx Oncology Holdings  RCUS Arcus Biosciences BCYC Bicycle Therapeutics Ltd CHRS Coherus BioSciences IONS Ionis Pharmaceuticals MESO Mesoblast Ltd NTLA Intellia Therapeutics RGLS Regulus Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$2

$1.82 (1011.11%)

$5

6 years 5 months 9 days ago
(02-May-2019)

2/3 (66.67%)

$-0.96 (-32.43%)

528

Hold

$4

7 years 8 months 4 days ago
(07-Feb-2018)

4/4 (100%)

$-0.81 (-16.84%)

106

Buy

$5

$4.82 (2677.78%)

$6

7 years 10 months 1 days ago
(10-Dec-2017)

0/4 (0%)

$2.14 (74.83%)

Buy

$10

8 years 1 months ago
(11-Sep-2017)

0/2 (0%)

$5.79 (137.53%)

Hold

$4

$3.82 (2122.22%)

$5

8 years 1 months 1 days ago
(10-Sep-2017)

6/7 (85.71%)

$0.17 (4.44%)

49

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Alethia Young?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?